Antiviral drugs for treatment of arenavirus infection
Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by the Arenavirus family such as Lassa fever, Argentine hemorrhagic fever, Bolivian hemorrhagic fever, and Venezuelan hemorrhagic fever.
1. A compound selected from the group consisting of:
1-(4-ethoxyphenyl)-N-[(4-ethylphenyl)methyl]indol-5-amine,
3-(4-ethoxyphenyl)-N-[(4-ethylphenyl)methyl]-1H-indol-6-amine,
1-(4-ethoxyphenyl)-N-[(4-ethylphenyl)methyl]pyrrolo[2,3-b]pyridin-5-amine,
1-(4-ethoxyphenyl)-5-[2-(4-ethylphenyl)ethyl]benzimidazole;
3-(4-ethoxyphenyl)-6-[2-(4-ethylphenyl)-ethyl]imidazo[4,5-b]pyridine,
1-(4-ethoxyphenyl)-5-[(4-ethylphenyl)-methoxy]benzimidazole,
5-[(4-isopropylphenyl)methoxy]-1-(4-methoxyphenyl)benzimidazole,
3-(4-ethoxyphenyl)-6-[(4-ethylphenyl)methoxy]imidazo[4,5-b]pyridine,
6-[(4-isopropylphenyl)methoxy]-3-(4-methoxyphenyl)imidazo[4,5-b]pyridine,
1-(4-ethoxyphenyl)-5-[(4-ethylphenyl)methylsulfanyl]benzimidazole,
5-[12-(4-tert-butylphenyl)cyclopropyl]-1-(4-isopropoxyphenyl)benzimidazole, and
pharmaceutically acceptable salts thereof.
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound of claim 1 or a pharmaceutically acceptable salt thereof.